CA2710646C - Asparaginase encapsulated in red corpuscles for the treatment of cancer of the pancreas - Google Patents
Asparaginase encapsulated in red corpuscles for the treatment of cancer of the pancreas Download PDFInfo
- Publication number
- CA2710646C CA2710646C CA2710646A CA2710646A CA2710646C CA 2710646 C CA2710646 C CA 2710646C CA 2710646 A CA2710646 A CA 2710646A CA 2710646 A CA2710646 A CA 2710646A CA 2710646 C CA2710646 C CA 2710646C
- Authority
- CA
- Canada
- Prior art keywords
- asparaginase
- suspension
- treatment
- composition
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
- C12Y305/01001—Asparaginase (3.5.1.1)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Botany (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0760345 | 2007-12-24 | ||
FR0760345A FR2925339B1 (fr) | 2007-12-24 | 2007-12-24 | Medicament pour le traitement du cancer du pancreas |
PCT/EP2008/068289 WO2009080837A1 (en) | 2007-12-24 | 2008-12-24 | Medicament for the treatment of cancer of the pancreas |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2710646A1 CA2710646A1 (en) | 2009-07-02 |
CA2710646C true CA2710646C (en) | 2017-08-22 |
Family
ID=39322665
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2710646A Active CA2710646C (en) | 2007-12-24 | 2008-12-24 | Asparaginase encapsulated in red corpuscles for the treatment of cancer of the pancreas |
Country Status (17)
Country | Link |
---|---|
US (1) | US8974802B2 (ko) |
EP (1) | EP2224950B1 (ko) |
JP (2) | JP5932218B2 (ko) |
KR (1) | KR101605838B1 (ko) |
CN (2) | CN101932335A (ko) |
AU (1) | AU2008339918B2 (ko) |
CA (1) | CA2710646C (ko) |
DK (1) | DK2224950T3 (ko) |
ES (1) | ES2537315T3 (ko) |
FR (1) | FR2925339B1 (ko) |
HK (1) | HK1224200A1 (ko) |
HR (1) | HRP20150498T1 (ko) |
IL (1) | IL206563A (ko) |
PL (1) | PL2224950T3 (ko) |
PT (1) | PT2224950E (ko) |
SI (1) | SI2224950T1 (ko) |
WO (1) | WO2009080837A1 (ko) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2938332B1 (fr) * | 2008-11-07 | 2011-11-25 | Erytech Pharma | Test predictif de la neutralisation de l'activite asparaginase |
WO2012021512A2 (en) | 2010-08-10 | 2012-02-16 | Ecole Polytechnique Federale De Lausanne | Erythrocyte-binding therapeutics |
US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
JP6194350B2 (ja) * | 2012-03-21 | 2017-09-06 | エリテック・ファルマ | 急性骨髄性白血病(aml)の処置のための薬剤 |
WO2015073587A2 (en) | 2013-11-18 | 2015-05-21 | Rubius Therapeutics, Inc. | Synthetic membrane-receiver complexes |
FR3017299B1 (fr) | 2014-02-12 | 2018-05-18 | Erytech Pharma | Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur |
US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
AU2015233084B2 (en) | 2014-02-21 | 2020-12-17 | Anokion Sa | Glycotargeting therapeutics |
US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
EP3125927B1 (en) | 2014-04-01 | 2021-01-27 | Rubius Therapeutics, Inc. | Methods and compositions for immunomodulation |
WO2017050651A1 (en) * | 2015-09-25 | 2017-03-30 | Dsm Ip Assets B.V. | Asparaginase |
WO2017050654A1 (en) * | 2015-09-25 | 2017-03-30 | Dsm Ip Assets B.V. | Asparaginase |
US20180273929A1 (en) * | 2015-09-25 | 2018-09-27 | Dsm Ip Assets B.V. | Asparaginase |
LT3402491T (lt) | 2016-01-11 | 2022-02-25 | Rubius Therapeutics, Inc. | Kompozicijos ir būdai, susiję su daugiamodalinėmis terapinėmis ląstelių sistemomis, skirti vėžio indikacijoms |
SG10202105661TA (en) * | 2016-12-02 | 2021-07-29 | Rubius Therapeutics Inc | Compositions and methods related to cell systems for penetrating solid tumors |
EP3638296A1 (en) | 2017-06-16 | 2020-04-22 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
CA3111126A1 (en) | 2018-08-31 | 2020-03-05 | Stichting Katholieke Universiteit | Synergistic combinations of amino acid depletion agent sensitizers (aadas) and amino acid depletion agents (aada), and therapeutic methods of use thereof |
EP4149440A1 (en) | 2020-05-11 | 2023-03-22 | Erytech Pharma | Red cell extracellular vesicles (rcevs) containing cargoes and methods of use and production thereof |
WO2023067200A1 (en) * | 2021-10-24 | 2023-04-27 | Erytech Pharma | Asparaginase encapsulated in red blood cells for the treatment of pancreatic cancer |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2873925B1 (fr) * | 2004-08-05 | 2006-10-13 | Erytech Pharma Soc Par Actions | Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes |
WO2007103290A2 (en) * | 2006-03-03 | 2007-09-13 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Materials and methods directed to asparagine synthetase and asparaginase therapies |
-
2007
- 2007-12-24 FR FR0760345A patent/FR2925339B1/fr active Active
-
2008
- 2008-12-24 CA CA2710646A patent/CA2710646C/en active Active
- 2008-12-24 US US12/810,164 patent/US8974802B2/en active Active
- 2008-12-24 KR KR1020107016332A patent/KR101605838B1/ko active IP Right Grant
- 2008-12-24 AU AU2008339918A patent/AU2008339918B2/en active Active
- 2008-12-24 CN CN2008801260460A patent/CN101932335A/zh active Pending
- 2008-12-24 PT PT88641691T patent/PT2224950E/pt unknown
- 2008-12-24 PL PL08864169T patent/PL2224950T3/pl unknown
- 2008-12-24 DK DK08864169T patent/DK2224950T3/en active
- 2008-12-24 JP JP2010540140A patent/JP5932218B2/ja active Active
- 2008-12-24 EP EP08864169.1A patent/EP2224950B1/en active Active
- 2008-12-24 CN CN201610012474.7A patent/CN105617366A/zh active Pending
- 2008-12-24 WO PCT/EP2008/068289 patent/WO2009080837A1/en active Application Filing
- 2008-12-24 SI SI200831419T patent/SI2224950T1/sl unknown
- 2008-12-24 ES ES08864169.1T patent/ES2537315T3/es active Active
-
2010
- 2010-06-23 IL IL206563A patent/IL206563A/en active IP Right Grant
-
2015
- 2015-01-09 JP JP2015003254A patent/JP2015091859A/ja active Pending
- 2015-05-11 HR HRP20150498TT patent/HRP20150498T1/hr unknown
-
2016
- 2016-11-01 HK HK16112530.4A patent/HK1224200A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
PL2224950T3 (pl) | 2015-08-31 |
ES2537315T3 (es) | 2015-06-05 |
US20100310612A1 (en) | 2010-12-09 |
JP2011507935A (ja) | 2011-03-10 |
US8974802B2 (en) | 2015-03-10 |
DK2224950T3 (en) | 2015-03-23 |
EP2224950B1 (en) | 2015-02-25 |
AU2008339918A1 (en) | 2009-07-02 |
KR101605838B1 (ko) | 2016-03-24 |
SI2224950T1 (sl) | 2015-08-31 |
AU2008339918B2 (en) | 2012-09-20 |
WO2009080837A1 (en) | 2009-07-02 |
JP2015091859A (ja) | 2015-05-14 |
CA2710646A1 (en) | 2009-07-02 |
FR2925339B1 (fr) | 2010-03-05 |
IL206563A (en) | 2013-09-30 |
CN105617366A (zh) | 2016-06-01 |
EP2224950A1 (en) | 2010-09-08 |
JP5932218B2 (ja) | 2016-06-08 |
FR2925339A1 (fr) | 2009-06-26 |
PT2224950E (pt) | 2015-05-18 |
HRP20150498T1 (hr) | 2015-06-19 |
IL206563A0 (en) | 2010-12-30 |
CN101932335A (zh) | 2010-12-29 |
HK1224200A1 (zh) | 2017-08-18 |
KR20100102676A (ko) | 2010-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2710646C (en) | Asparaginase encapsulated in red corpuscles for the treatment of cancer of the pancreas | |
Cronin et al. | The role of iron regulation in immunometabolism and immune-related disease | |
US20150086521A1 (en) | Medicament for the Treatment of Acute Myeloid Leukemia (AML) | |
Rossi et al. | Erythrocyte-mediated delivery of phenylalanine ammonia lyase for the treatment of phenylketonuria in BTBR-Pahenu2 mice | |
EP3397272B1 (en) | Methionine and asparagine depletion for use in treating a cancer | |
ES2405258T3 (es) | Formulación y procedimiento para la prevención y el tratamiento de la manifestación esquelética de la enfermedad de Gaucher | |
ES2782828T3 (es) | Composición de eritrocitos que encapsulan fenilalanina hidroxilasa y utilización terapéutica de la misma | |
Dumas et al. | Raising the ‘good’oxidants for immune protection | |
Kumarl et al. | Resealed erythrocytes as a carrier for drug targeting: a review | |
US9763889B2 (en) | Oral delivery system for hemoglobin based oxygen carriers | |
Kumar et al. | Resealed Erythrocytes as a Carrier for Drug Targeting: A |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20131210 |